Residents of a Nursing Home who choose monthly Vitamin D had 4X fewer COVID-19 deaths – Nov 2, 2020

---

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Nutrients 2020, 12(11), 3377; https://doi.org/10.3390/nu12113377
by Gaëlle Annweiler 1,2, Mathieu Corvaisier 3,4, Jennifer Gautier 3, Vincent Dubée 1,5,6, Erick Legrand 1,7, Guillaume Sacco 3,8 and Cédric Annweiler 1,3,8,9,10,* on behalf of the GERIA-COVID study group
Chart of data by VitaminDWiki

Review of Study by Grassroots Health

Background. The objective of this quasi-experimental study was to determine whether bolus vitamin D supplementation taken either regularly over the preceding year or after the diagnosis of COVID-19 was effective in improving survival among hospitalized frail elderly COVID-19 patients.

Methods. Seventy-seven patients consecutively hospitalized for COVID-19 in a geriatric unit were included. Intervention groups were participants regularly supplemented with vitamin D over the preceding year (Group 1), and those supplemented with vitamin D after COVID-19 diagnosis (Group 2). The comparator group involved participants having received no vitamin D supplements (Group 3). Outcomes were 14-day mortality and highest (worst) score on the ordinal scale for clinical improvement (OSCI) measured during COVID-19 acute phase. Potential confounders were age, gender, functional abilities, undernutrition, cancer, hypertension, cardiomyopathy, glycated hemoglobin, number of acute health issues at admission, hospital use of antibiotics, corticosteroids, and pharmacological treatments of respiratory disorders.

Results. The three groups (n = 77; mean ± SD, 88 ± 5years; 49% women) were similar at baseline (except for woman proportion, p = 0.02), as were the treatments used for COVID-19. In Group 1 (n = 29), 93.1% of COVID-19 participants survived at day 14, compared to 81.2% survivors in Group 2 (n = 16) (p = 0.33) and 68.7% survivors in Group 3 (n = 32) (p = 0.02). While considering Group 3 as reference (hazard ratio (HR) = 1), the fully-adjusted HR for 14-day mortality was HR = 0.07 (p = 0.017) for Group 1 and HR = 0.37 (p = 0.28) for Group 2. Group 1 had longer survival time than Group 3 (log-rank p = 0.015), although there was no difference between Groups 2 and 3 (log-rank p = 0.32). Group 1, but not Group 2 (p = 0.40), was associated with lower risk of OSCI score ≥5 compared to Group 3 (odds ratio = 0.08, p= 0.03).

Conclusions. Regular bolus vitamin D supplementation was associated with less severe COVID-19 and better survival in frail elderly.
 Download the PDF from VitaminDWiki

---

French National Academy recommended 100,000 IU of Vitamin D to elderly to fight COVID-19 - May 2020

COVID-19 treated by Vitamin D - studies, reports, videos in VitaminDWiki

As of Dec 1: 36 trials, 4 trial results, 3 meta-analyses, 32 observations, 15 recommendations, 35 associations, 80 speculations, 29 videos

Top Vitamin D and COVID-19 recent updates

• Evidence of Vitamin D fighting COVID-19 etc. - 4,000 IU if less than 20 ng (UK) – Dec 1, 2020
• 1.4X less risk of COVID-19 if had taken some Vitamin D (a US yes-no survey) – Nov 30, 2020
• COVID-19 and Vitamin D: Health Authorities do not understand risk-reward – Nov 2020
• c19study.com/d has excellent synopsis of Vitamin D and COVID studies
  •   click to see 3 weeks in Nov 2020
• COVID-19 – Putative Roles of Vitamin D – Nov 2020
• Fight COVID-19 without drugs or vaccines, Vitamin D is the single most-studied way – Nov 2020
• Clinical trials are proving that Vitamin D fights COVID-19 in hospitals by VitaminDWiki
• Vitamin D should fight COVID-19 (but Irish Consortium recommends only 1,000 IU) – Nov 21, 2020
• Hospital COVID-19 observation: 7X more likely to live if more than 20 ng of vitamin D– Nov 19, 2020
• Severe COVID-19 not fought by vitamin D when given too late - RCT Nov 18, 2020
• Higher vitamin D associated with fewer cases and deaths in India Nov 2020
  • 
• COVID-19 defeated 3x faster by 420,000 IU Vitamin D nanoemulsion – RCT Nov 12, 2020
• 2X fewer COVID-19 deaths observed if infrequent vitamin D (2X more deaths if daily dose) – ClinicalTrial Oct 20, 2020
• Vitamin D fighting COVID-19 meets all Bradford Hill Criteria - Nov 2020
• French National Academy recommended 100,000 IU of Vitamin D to elderly to fight COVID-19 - May 2020
• Chinese COVID-19 study – 80 pct of severe cases had low Vitamin D, all asymptomatic cases had OK Vit D – Oct 13, 2020
• Vitamin D and COVID-19 - observational studies found it helps, never hurts - Campbell Oct 31, 2020
• Low Vitamin D associated 1.8X increased risk of COVID-19 death in hosptial – meta-analysis Nov 4, 2020
• COVID-19 lung death 4X more likely in Iran if less than 25 ng of vitamin D – Oct 30, 2020
• Evidence Regarding Vitamin D and Risk of COVID-19 and its Severity - Oct 27, 2020
• COVID-19 patients who happened to be taking Vitamin D did much better – Oct 27,2020
• 9X COVID-19 survival in nursing home if had 80,000 IU dose of vitamin D in previous month – Oct 2020
• COVID-19 fought by Vitamin D in 43 studies - Oct 15, 2020
• 15 studies indicating that Vitamin D fights COVID-19 - Dr. Grimes Oct 9, 2020
• 32X more likely to have severe-critical COVID-19 in Turkish hospital if Vitamin D deficient – Oct 5, 2020
  • 
• Vitamin D Cuts SARS-CoV-2 Infection Rate by Half Mercola Sept 28
  • 47% lower SARS-CoV-2 positivity rate if > 50 ng vs < 20 ng
  • 58% lower risk of testing positive for SARS-CoV-2 if > 30 ng vs < 30 ng
  • 2X higher risk of hospitialization if <30 ng
  • ICU patients got semi-activated Vitamin D - death rate dropped to 2% from 50%
• Virtually no COVID-19 cases in countries having more than 30 ng of Vitamin D - Sept 17, 2020
  • 
• Studies on Vitamin D and COVID-19 (11 categories) - Sept 20, 2020
• Rate of COVID-19 test positive is 40 pcnt lower if high vitamin D (192,000 people) - Holick Sept 2020
  • 
• Vitamin D in Prevention and Treatment of COVID-19 (16 reasons) – Sept 1, 2020

Many clinical trials expect that high Vitamin D loading doses will fight COVID-19

Note: The highlighted author of this paper is the Principal Investigator for Clinical Trial #5

Title change made Nov 2020 caused the visitor count to reset.
There have actually been 653 visitors to this page since it was originally made